International Study to Predict Optimised Treatment - in Depression

The aim of this study is to identify genetic, physical (brain) and psychological (cognitive) markers (or combinations of them) that predict specific response to a range of antidepressants treatment (Escitalopram, Venlafaxine, Sertraline) in patients diagnosed with major depressive disorder. This study is focused on outcomes which may impact on how "personalised medicine" is implemented in depression.

Stanford is now accepting new patients for this trial. Please contact Maureen Chang at 7254620 for more information.

Investigator(s):

Intervention(s):

  • drug : Escitalopram
  • drug : Venlafaxine XR
  • drug : Sertraline

Phase: Phase 4

Eligibility

Ages Eligible For Study:

18 Years - 65 Years

Inclusion Criteria

- Meet DSM-IV criteria for primary diagnosis of MDD. - HAM-D17 score of ? 16. - 18-65 years age-range - Subjects with English or Dutch literacy and fluency. - Written, informed consent.

External Links

Contact information

Primary Contact:

Maureen Chang 7254620

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: